Health
Dupilumab considerably reduced asthma exacerbations in young children, shows VOYAGE trial – News-Medical.Net
Results from the VOYAGE study of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children ages 6-11 with uncontrolled…
Results from the VOYAGE study of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children ages 6-11 with uncontrolled moderate-to-severe asthma, compared to placebo, according to research presented at the ATS 2021 International Conference. VOYAGE (NCT02948959) is a recently completed randomized, placebo-controlled double-blind multicenter phase 3 clinical trial, that took place in a number of countries.
Dupilumab also rapidly improved lung function…
-
Noosa News21 hours agoWilliam Robinson dies aged 89
-
Noosa News21 hours agoTwo-time Archibald Prize-winning painter William Robinson has died, aged 89
-
General21 hours agoCalls for corruption probe into completion of mayor’s Surfers Paradise Bowls Club site purchase
-
General21 hours agoMatt Wright wanted to hinder investigations into chopper crash ‘at almost any cost’, jury hears